retatrutide parkinson disease clinical trial Parkinson's Drug Therapies in the Pipeline: 2020 Liraglutide once daily versus placebo

2023;7:e53619

Barrera et al., 2010)

Biotechnology companies invest heavily in research and development which may not necessarily lead to commercially successful products

Corroborating these findings, other GLP-1RAs have similarly shown neuroprotective properties in murine models of ocular hypertensive glaucoma, manifesting as enhanced RGC survival, reduced microglial/macrophage activation, and amelioration of optic nerve axon degeneration [46]

The urine albumin to creatinine ratio fluctuates by 30 to 40% on the basis of several factors, such as the presence of a fever, dehydration, vigorous physical activity or urinary tract infection

I prefer to recommend medication use as close to the manufacturers recommendations as possible, or that which is supported by research. But Jaclyn Pritchard, registered dietician and leader of the weight management program at Cleveland Clinic Canada, thinks there is room for personalization when taking GLP-1 medications